drugset / Trial / NCT01896180

Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost

NCT01896180

Phase 2 Completed 63 enrolled Alleanza Pharmaceuticals, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a pilot, proof of concept study to evaluate the safety and efficacy of ALZ-1101 dosed once daily for 28 days compared to latanoprost 0.005% ophthalmic solution in patients with elevated intraocular pressure not adequately controlled with latanoprost.

Timeline

Start
2013-07
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ALZ-1101 Unknown Topical
Comparator Latanoprost Small molecule 0.005 % Topical